These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
826 related items for PubMed ID: 29066048
21. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Klein EA, Chait A, Hafron JM, Kernen KM, Manickam K, Stephenson AJ, Wagner M, Zhu H, Kestranek A, Zaslavsky B, Stovsky M. Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176 [Abstract] [Full Text] [Related]
22. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer? Beckmann K, Kinsella N, Olsson H, Wallerstedt Lantz A, Nordstrom T, Aly M, Adolfsson J, Eklund M, Van Hemelrijck M. BMC Urol; 2019 Aug 05; 19(1):73. PubMed ID: 31383015 [Abstract] [Full Text] [Related]
23. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis. Liu S, Wang XY, Huang TB, Niu Q, Yao K, Song X, Zhou SY, Chen Z, Zhou GC. Ann Palliat Med; 2020 Jul 05; 9(4):1708-1717. PubMed ID: 32527134 [Abstract] [Full Text] [Related]
25. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL. Faria EF, Carvalhal GF, dos Reis RB, Tobias-Machado M, Vieira RA, Reis LO, Nogueira L, Machado RD, Freitas CH, Magnabosco WJ, Mauad EC, Carvalho AL. BJU Int; 2012 Dec 05; 110(11 Pt B):E653-7. PubMed ID: 22892057 [Abstract] [Full Text] [Related]
26. Is further screening of men with baseline PSA < 1 ng ml(-1) worthwhile? The discussion continues-Results of the Swiss ERSPC (Aarau). Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Kluth LA, Wyler SF, Recker F, Kwiatkowski M. Int J Cancer; 2015 Aug 01; 137(3):553-9. PubMed ID: 25565393 [Abstract] [Full Text] [Related]
27. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Eur Urol; 2012 Nov 01; 62(5):757-64. PubMed ID: 22658758 [Abstract] [Full Text] [Related]
29. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH. Eur Urol; 2012 Mar 01; 61(3):577-83. PubMed ID: 22104592 [Abstract] [Full Text] [Related]
30. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. Aly M, Clements M, Weibull CE, Nordström T, Näslund E, Adolfsson J, Grönberg H. Eur Urol Focus; 2019 Sep 01; 5(5):842-848. PubMed ID: 29433987 [Abstract] [Full Text] [Related]
33. Prostate cancer screening in the fit Chilean elderly: a head to head comparison of total serum PSA versus age adjusted PSA versus primary circulating prostate cells to detect prostate cancer at initial biopsy. Murray NP, Reyes E, Orellana N, Fuentealba C, Jacob O. Asian Pac J Cancer Prev; 2015 Sep 01; 16(2):601-6. PubMed ID: 25684494 [Abstract] [Full Text] [Related]
34. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. García-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A. BJU Int; 2012 Dec 01; 110(11 Pt B):E541-6. PubMed ID: 22584031 [Abstract] [Full Text] [Related]
36. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV. Cancer; 2007 Nov 01; 110(9):1973-8. PubMed ID: 17886252 [Abstract] [Full Text] [Related]
37. Variation of Prostate-specific Antigen Value in Men and Risk of High-grade Prostate Cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study. Boniol M, Autier P, Perrin P, Boyle P. Urology; 2015 May 01; 85(5):1117-1122. PubMed ID: 25917734 [Abstract] [Full Text] [Related]
38. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A. Eur Urol; 2016 Jun 01; 69(6):1142-8. PubMed ID: 26749093 [Abstract] [Full Text] [Related]
40. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. de Vos II, Remmers S, Hogenhout R, Roobol MJ, ERSPC Rotterdam Study GroupErasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.. Eur Urol; 2024 Jan 01; 85(1):74-81. PubMed ID: 37919190 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]